GlassScriptPhysician profile
Gwendolyn Roberts
NPI 1386397651
$1,758.86
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $1,171 · 2024: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $304.34 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $288.40 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.49 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $248.56 | 2022-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $163.36 | 2022-2023 | Invega Sustenna, Spravato |
| Tris Pharma INC | $109.00 | 2023-2024 | Dyanavel Xr |
| Lundbeck LLC | $93.62 | 2023-2024 | Rexulti |
| Alkermes, INC. | $91.29 | 2022-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $66.34 | 2023-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $27.59 | 2023 | Quviviq |
| Corium, LLC | $27.48 | 2023 | Azstarys |
| Abiomed | $18.03 | 2024 | Impella |
| Teva Pharmaceuticals USA, INC. | $18.01 | 2023 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $14.77 | 2023 | Trintellix |
| Merck Sharp & Dohme LLC | $13.58 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gwendolyn Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.